| Literature DB >> 29779826 |
Phillip J White1, Robert W McGarrah1, Paul A Grimsrud2, Shih-Chia Tso3, Wen-Hsuan Yang2, Jonathan M Haldeman2, Thomas Grenier-Larouche2, Jie An2, Amanda L Lapworth2, Inna Astapova1, Sarah A Hannou2, Tabitha George2, Michelle Arlotto2, Lyra B Olson2, Michelle Lai4, Guo-Fang Zhang1, Olga Ilkayeva2, Mark A Herman1, R Max Wynn3, David T Chuang3, Christopher B Newgard5.
Abstract
Branched-chain amino acids (BCAA) are strongly associated with dysregulated glucose and lipid metabolism, but the underlying mechanisms are poorly understood. We report that inhibition of the kinase (BDK) or overexpression of the phosphatase (PPM1K) that regulates branched-chain ketoacid dehydrogenase (BCKDH), the committed step of BCAA catabolism, lowers circulating BCAA, reduces hepatic steatosis, and improves glucose tolerance in the absence of weight loss in Zucker fatty rats. Phosphoproteomics analysis identified ATP-citrate lyase (ACL) as an alternate substrate of BDK and PPM1K. Hepatic overexpression of BDK increased ACL phosphorylation and activated de novo lipogenesis. BDK and PPM1K transcript levels were increased and repressed, respectively, in response to fructose feeding or expression of the ChREBP-β transcription factor. These studies identify BDK and PPM1K as a ChREBP-regulated node that integrates BCAA and lipid metabolism. Moreover, manipulation of the BDK:PPM1K ratio relieves key metabolic disease phenotypes in a genetic model of severe obesity.Entities:
Keywords: ATP-citrate lyase; branched-chain amino acids; diabetes; lipid metabolism; obesity; systems physiology
Mesh:
Substances:
Year: 2018 PMID: 29779826 PMCID: PMC5990471 DOI: 10.1016/j.cmet.2018.04.015
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 31.373